These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 18778291)

  • 21. [Thymoglobulin efficiently expands cytokine-induced killer cells in a clinical-grade culture protocol].
    Chen W; Lin D; Jiang Z; Yang Z; Song S; Zhou J; Zhou L; Sun Y; Yu H; Ma D
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jul; 30(7):681-5, 690. PubMed ID: 25001928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Multiplex and genome-wide analyses reveal distinctive properties of KIR+ and CD56+ T cells in human blood.
    Chan WK; Rujkijyanont P; Neale G; Yang J; Bari R; Das Gupta N; Holladay M; Rooney B; Leung W
    J Immunol; 2013 Aug; 191(4):1625-36. PubMed ID: 23858032
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A new method for in vitro expansion of cytotoxic human CD3-CD56+ natural killer cells.
    Carlens S; Gilljam M; Chambers BJ; Aschan J; Guven H; Ljunggren HG; Christensson B; Dilber MS
    Hum Immunol; 2001 Oct; 62(10):1092-8. PubMed ID: 11600215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HER-2/neu-derived peptide epitopes are also recognized by cytotoxic CD3(+)CD56(+) (natural killer T) lymphocytes.
    Baxevanis CN; Gritzapis AD; Tsitsilonis OE; Katsoulas HL; Papamichail M
    Int J Cancer; 2002 Apr; 98(6):864-72. PubMed ID: 11948464
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Severe chronic autoimmune thrombocytopenic purpura is associated with an expansion of CD56+ CD3- natural killer cells subset.
    Garcia-Suarez J; Prieto A; Reyes E; Manzano L; Merino JL; Alvarez-Mon M
    Blood; 1993 Sep; 82(5):1538-45. PubMed ID: 7689873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct granzyme expression in human CD3- CD56+ large granular- and CD3- CD56+ small high density-lymphocytes displaying non-MHC-restricted cytolytic activity.
    Smyth MJ; Browne KA; Kinnear BF; Trapani JA; Warren HS
    J Leukoc Biol; 1995 Jan; 57(1):88-93. PubMed ID: 7530284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhancement of MHC-unrestricted cytotoxic activity of human CD56+ CD3- natural killer (NK) cells and CD3+ T cells by rhamnogalacturonan: target cell specificity and activity against NK-insensitive targets.
    Zhu HG; Zollner TM; Klein-Franke A; Anderer FA
    J Cancer Res Clin Oncol; 1994; 120(7):383-8. PubMed ID: 7514604
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of killer cell inhibitory receptors is restricted to true NK cell lymphomas and a subset of intestinal enteropathy-type T cell lymphomas with a cytotoxic phenotype.
    Dukers DF; Vermeer MH; Jaspars LH; Sander CA; Flaig MJ; Vos W; Willemze R; Meijer CJ
    J Clin Pathol; 2001 Mar; 54(3):224-8. PubMed ID: 11253136
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lipopolysaccharide stimulates the proliferation of human CD56+CD3- NK cells: a regulatory role of monocytes and IL-10.
    Goodier MR; Londei M
    J Immunol; 2000 Jul; 165(1):139-47. PubMed ID: 10861046
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential expression of CD8 alpha and CD8 beta associated with MHC-restricted and non-MHC-restricted cytolytic effector cells.
    Baume DM; Caligiuri MA; Manley TJ; Daley JF; Ritz J
    Cell Immunol; 1990 Dec; 131(2):352-65. PubMed ID: 2122925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric antigen receptor-engineered cytokine-induced killer cells overcome treatment resistance of pre-B-cell acute lymphoblastic leukemia and enhance survival.
    Oelsner S; Wagner J; Friede ME; Pfirrmann V; Genßler S; Rettinger E; Buchholz CJ; Pfeifer H; Schubert R; Ottmann OG; Ullrich E; Bader P; Wels WS
    Int J Cancer; 2016 Oct; 139(8):1799-809. PubMed ID: 27253354
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytotoxic potential of IL-15-activated cytokine-induced killer cells against human neuroblastoma cells.
    Cappel C; Huenecke S; Suemmerer A; Erben S; Rettinger E; Pfirrmann V; Heinze A; Zimmermann O; Klingebiel T; Ullrich E; Bader P; Bremm M
    Pediatr Blood Cancer; 2016 Dec; 63(12):2230-2239. PubMed ID: 27433920
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NKG2D Engagement Alone Is Sufficient to Activate Cytokine-Induced Killer Cells While 2B4 Only Provides Limited Coactivation.
    Wu X; Sharma A; Oldenburg J; Weiher H; Essler M; Skowasch D; Schmidt-Wolf IGH
    Front Immunol; 2021; 12():731767. PubMed ID: 34691037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phenotypic characterization and anticancer capacity of CD8+ cytokine-induced killer cells after antigen-induced expansion.
    Liu J; Wang L; Wang Y; Zhang W; Cao Y
    PLoS One; 2017; 12(4):e0175704. PubMed ID: 28426690
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can the dual-functional capability of CIK cells be used to improve antitumor effects?
    Wang X; Yu W; Li H; Yu J; Zhang X; Ren X; Cao S
    Cell Immunol; 2014 Jan; 287(1):18-22. PubMed ID: 24355711
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells.
    Igarashi T; Wynberg J; Srinivasan R; Becknell B; McCoy JP; Takahashi Y; Suffredini DA; Linehan WM; Caligiuri MA; Childs RW
    Blood; 2004 Jul; 104(1):170-7. PubMed ID: 15016654
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumor infiltrating NK cell (TINK) subsets and functional molecules in patients with breast cancer.
    Rezaeifard S; Talei A; Shariat M; Erfani N
    Mol Immunol; 2021 Aug; 136():161-167. PubMed ID: 34171565
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural killer cell subsets and their functional molecules in peripheral blood of the patients with breast cancer.
    Darvishvand R; Rezaeifard S; Kiani R; Tahmasebi S; Faghih Z; Erfani N
    Immun Inflamm Dis; 2024 Apr; 12(4):e1255. PubMed ID: 38652012
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implication of different effector mechanisms by cord blood-derived and peripheral blood-derived cytokine-induced killer cells to kill precursor B acute lymphoblastic leukemia cell lines.
    Durrieu L; Lemieux W; Dieng MM; Fontaine F; Duval M; Le Deist F; Haddad E
    Cytotherapy; 2014 Jun; 16(6):845-56. PubMed ID: 24529554
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Large-scale expansion of CD3(+)CD56(+) lymphocytes capable of lysing autologous tumor cells with cytokine-rich supernatants.
    Gritzapis AD; Dimitroulopoulos D; Paraskevas E; Baxevanis CN; Papamichail M
    Cancer Immunol Immunother; 2002 Oct; 51(8):440-8. PubMed ID: 12202905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.